Abstract
Background:EGFR mutations cause inconsistent response to EGFR tyrosine kinase inhibitors (TKI). To better understand these features, we reviewed all cases of EGFR-mutated NSCLC collected in the Biomarkers France database.Patients and methods: Of 17,664 patients, 1,837 (11%) with EGFR-mutated non-small cell lung cancer (NSCLC) were retrospectively analyzed for clinical and molecular characteristics. Results were correlated with survival and treatment response for the 848 Stage IV patients.Results:EGFR exon 18, 19, 20, and 21 mutations were found in 102 (5.5%), 931 (51%), 102 (5.5%), and 702 (38%) patients, respectively. Over 50% of exon 18 and 20 mutated patients were smokers. The median follow-up was 51.7 months. EGFR mutation type was prognostic of overall survival (OS) versus wild-type (WT) (exon 19: hazard ratio [HR]=0.51 [95% confidence interval [CI]: 0.41-0.64], p < 0.0001; exon 21: HR = 0.76 [95% CI: 0.61-0.95], p = 0.002; exon 20: HR = 1.56, [95% CI: 1.02-2.38], p = 0.004). EGFR mutation type was prognostic of progression-free survival (PFS) versus WT (exon 19: HR = 0.62 [95% CI: 0.49-0.78], p < 0.0001; exon 20: HR = 1.46 [95% CI: 0.96-2.21], p = 0.07). First-line treatment choice did not influence OS in multivariate analysis. First-line TKI predicted improved PFS versus chemotherapy (HR = 0.67 [95% CI: 0.53-0.85], p = 0.001). OS was longer for del19 versus L858R, which was associated with better OS compared to other exon 21 mutations, including L861Q. TKI improved survival in patients with exon 18 mutations, while chemotherapy was more beneficial for exon 20-mutated patients.Conclusion:EGFR mutation type can inform the most appropriate treatment. Therapeutic schedule had no impact on OS in our study, although TKI should be prescribed in first-line considering the risk of missing the opportunity to use this treatment.http://ift.tt/2h8jhRL
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου